Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Added MedlinePlus Genetics topic: Melanoma.
    Difference
    0.1%
    Check dated 2025-10-13T08:46:16.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Summary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.
    Difference
    2%
    Check dated 2025-10-06T05:37:50.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    Upgrade a page from Revision v3.0.2 to v3.1.0 and add a phone contact number (866-820-4505).
    Difference
    0.1%
    Check dated 2025-09-29T03:06:31.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    - The Melanoma topic under MedlinePlus Genetics has been removed from the page. This reduces the scope of genetic-related content available on the site.
    Difference
    0.1%
    Check dated 2025-09-21T22:40:27.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Version updated from v3.0.1 to v3.0.2. The 'Back to Top' navigation element was removed.
    Difference
    0.1%
    Check dated 2025-09-14T19:12:21.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    The web page has been updated to include information on Melanoma under MedlinePlus Genetics topics, and the version has been revised from v3.0.0 to v3.0.1.
    Difference
    0.3%
    Check dated 2025-09-07T15:22:27.000Z thumbnail image

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.